CKD-Mineral Bone Disorder

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is the systemic disturbance of mineral and bone metabolism that develops as kidney function declines. It links abnormalities of calcium, phosphate, parathyroid hormone, and vitamin D to changes in bone structure and to vascular and soft-tissue calcification, making it a disorder of the whole skeletal-vascular axis rather than of bone alone.

Definition

CKD-MBD is a systemic disorder of mineral and bone metabolism due to CKD, manifested by abnormalities of calcium, phosphate, parathyroid hormone, or vitamin D metabolism; abnormalities of bone turnover, mineralization, volume, or strength; and vascular or other soft-tissue calcification.

Scope

This topic covers how failing kidneys disturb phosphate excretion and vitamin D activation, the resulting endocrine cascade involving fibroblast growth factor 23, parathyroid hormone, and calcitriol, the consequences for bone (renal osteodystrophy) and blood vessels (calcification), and the prognostic associations of these abnormalities. It is a reference account of the disorder and its evidence base, not individualized treatment guidance.

Core questions

• How does declining kidney function disturb phosphate, calcium, and vitamin D?
• What is the role of FGF23 and parathyroid hormone in CKD-MBD?
• How does the disorder connect bone disease to vascular calcification?
• Why are mineral abnormalities associated with worse outcomes in CKD?

Key concepts

• Phosphate retention
• Reduced calcitriol (active vitamin D) synthesis
• Fibroblast growth factor 23 (FGF23)
• Secondary hyperparathyroidism
• Renal osteodystrophy
• Vascular and soft-tissue calcification
• Calcium-phosphate balance

Mechanisms

As GFR falls, the kidney retains phosphate and loses its capacity to convert vitamin D to its active form, calcitriol. Rising phosphate and falling calcitriol stimulate secretion of fibroblast growth factor 23 (FGF23) from bone and of parathyroid hormone (PTH) from the parathyroid glands; FGF23 initially promotes phosphate excretion but also suppresses calcitriol, while sustained PTH elevation produces secondary hyperparathyroidism and high-turnover bone disease. These hormonal disturbances, together with disordered calcium and phosphate balance, drive both abnormal bone (renal osteodystrophy) and deposition of calcium-phosphate in the vasculature, tying mineral metabolism to cardiovascular structure. Higher serum phosphate and PTH have been associated with increased mortality in CKD cohorts.

Clinical relevance

CKD-MBD explains why bone health and cardiovascular calcification are monitored as kidney function falls and why calcium, phosphate, PTH, and vitamin D are tracked together. This entry describes the disorder and summarizes its evidence base; it characterizes the abnormalities and their associations and does not specify targets, supplements, or medication doses for any individual.

Epidemiology

Biochemical features of CKD-MBD become increasingly common as CKD advances and are nearly ubiquitous in kidney failure, while vascular calcification is highly prevalent in dialysis populations. Disturbances in phosphate and parathyroid hormone are independently associated with mortality and cardiovascular events in observational cohorts.

History

Bone disease in kidney failure was long described as renal osteodystrophy, but recognition that the same metabolic disturbances also drive vascular calcification led KDIGO in 2009 to reframe the condition as the broader systemic syndrome CKD-MBD, updated in the 2017 guideline. The discovery of FGF23 as a phosphate-regulating hormone in the 2000s reshaped understanding of the underlying endocrine cascade.

Debates

Does lowering parathyroid hormone or phosphate improve hard outcomes?

Although phosphate and PTH abnormalities are strongly associated with mortality, randomized evidence that correcting these biochemical targets improves survival is limited; trials such as the cinacalcet study informed but did not fully resolve whether treating the numbers changes patient outcomes.

Key figures

• Markus Ketteler
• Geoffrey A. Block
• Bryan Kestenbaum

Seminal works

• ketteler-2017-kdigo-mbd
• kestenbaum-2005

Frequently asked questions

Why does kidney disease affect the bones?

Failing kidneys retain phosphate and make less active vitamin D, which raises parathyroid hormone and FGF23; the resulting hormonal imbalance disturbs bone turnover and mineralization, producing renal osteodystrophy.

How is CKD-MBD connected to the heart and blood vessels?

The same disturbances in calcium, phosphate, and regulatory hormones promote deposition of calcium-phosphate in the walls of arteries, so the disorder links bone disease to vascular calcification and cardiovascular risk.